Tier 3 — preclinical
Preclinical safety assessments of nicotinamide riboside hydrogen malate
Toxicology Research and Application
2022
6
Bibliography
- Funding
- The authors reported no financial support; Thorne Research supplied the test material.
- Competing interests
- The authors declared no potential conflicts of interest.
Study snapshot
| Design | Preclinical animal study with supporting assays as applicable |
|---|---|
| Model | Rats, bacterial cultures and isolated human lymphocytes |
| Sample | Sprague-Dawley rats, bacterial assays and human lymphocyte assays |
| Intervention | NR hydrogen malate at several doses, up to 3000 mg/kg/day |
| Duration | 14-day range finding and 90-day repeat-dose studies |
| Endpoints | Model-specific physiological outcomes; Biochemical or functional measures reported in the study |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
